AR and prostate carcinoma: Indeed, 2,4‐PDCA has been used to inhibit prostate cancer splicing in cells (AR V7 variant of the androgen receptor).[15] The IC50 values for the PHD inhibitors causing are particularly notable given that these compounds are in clinical use or have been in clinical development.